Antimycotics Market Size, Share, and Trends 2025 to 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology  

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Antimycotics Market 

5.1. COVID-19 Landscape: Antimycotics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Antimycotics Market, By Drug Class

8.1. Antimycotics Market Revenue and Volume, by Drug Class

8.1.1. Azoles

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Echinocandins

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Polyenes

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Allylamines

8.1.4.1. Market Revenue and Volume Forecast

8.1.5. Others

8.1.5.1. Market Revenue and Volume Forecast

Chapter 9. Global Antimycotics Market, By Infection Type

9.1. Antimycotics Market Revenue and Volume, by Infection Type

9.1.1. Systemic Infections

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Superficial Infections

9.1.2.1. Market Revenue and Volume Forecast

Chapter 10. Global Antimycotics Market, By Indication 

10.1. Antimycotics Market Revenue and Volume, by Indication

10.1.1. Candidiasis

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Dermatophytosis

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Aspergillosis

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Others

10.1.4.1. Market Revenue and Volume Forecast

Chapter 11. Global Antimycotics Market, By Route of Administration

11.1. Antimycotics Market Revenue and Volume, by Route of Administration

11.1.1. Oral

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Topical

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Injectable

11.1.3.1. Market Revenue and Volume Forecast

Chapter 12. Global Antimycotics Market, By End-User

12.1. Antimycotics Market Revenue and Volume, by End-User

12.1.1. Hospitals

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. Specialty Clinics

12.1.2.1. Market Revenue and Volume Forecast

12.1.3. Homecare

12.1.3.1. Market Revenue and Volume Forecast

12.1.4. Others

12.1.4.1. Market Revenue and Volume Forecast

Chapter 13. Global Antimycotics Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Volume Forecast, by Drug Class

13.1.2. Market Revenue and Volume Forecast, by Infection Type

13.1.3. Market Revenue and Volume Forecast, by Indication

13.1.4. Market Revenue and Volume Forecast, by Route of Administration

13.1.5. Market Revenue and Volume Forecast, by End-User

13.1.6. U.S.

13.1.6.1. Market Revenue and Volume Forecast, by Drug Class

13.1.6.2. Market Revenue and Volume Forecast, by Infection Type

13.1.6.3. Market Revenue and Volume Forecast, by Indication

13.1.6.4. Market Revenue and Volume Forecast, by Route of Administration

13.1.6.5. Market Revenue and Volume Forecast, by End-User  

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Volume Forecast, by Drug Class

13.1.7.2. Market Revenue and Volume Forecast, by Infection Type

13.1.7.3. Market Revenue and Volume Forecast, by Indication

13.1.7.4. Market Revenue and Volume Forecast, by Route of Administration

13.1.7.5. Market Revenue and Volume Forecast, by End-User

13.2. Europe

13.2.1. Market Revenue and Volume Forecast, by Drug Class

13.2.2. Market Revenue and Volume Forecast, by Infection Type

13.2.3. Market Revenue and Volume Forecast, by Indication

13.2.4. Market Revenue and Volume Forecast, by Route of Administration  

13.2.5. Market Revenue and Volume Forecast, by End-User  

13.2.6. UK

13.2.6.1. Market Revenue and Volume Forecast, by Drug Class

13.2.6.2. Market Revenue and Volume Forecast, by Infection Type

13.2.6.3. Market Revenue and Volume Forecast, by Indication

13.2.7. Market Revenue and Volume Forecast, by Route of Administration  

13.2.8. Market Revenue and Volume Forecast, by End-User  

13.2.9. Germany

13.2.9.1. Market Revenue and Volume Forecast, by Drug Class

13.2.9.2. Market Revenue and Volume Forecast, by Infection Type

13.2.9.3. Market Revenue and Volume Forecast, by Indication

13.2.10. Market Revenue and Volume Forecast, by Route of Administration

13.2.11. Market Revenue and Volume Forecast, by End-User

13.2.12. France

13.2.12.1. Market Revenue and Volume Forecast, by Drug Class

13.2.12.2. Market Revenue and Volume Forecast, by Infection Type

13.2.12.3. Market Revenue and Volume Forecast, by Indication

13.2.12.4. Market Revenue and Volume Forecast, by Route of Administration

13.2.13. Market Revenue and Volume Forecast, by End-User

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Volume Forecast, by Drug Class

13.2.14.2. Market Revenue and Volume Forecast, by Infection Type

13.2.14.3. Market Revenue and Volume Forecast, by Indication

13.2.14.4. Market Revenue and Volume Forecast, by Route of Administration

13.2.15. Market Revenue and Volume Forecast, by End-User

13.3. APAC

13.3.1. Market Revenue and Volume Forecast, by Drug Class

13.3.2. Market Revenue and Volume Forecast, by Infection Type

13.3.3. Market Revenue and Volume Forecast, by Indication

13.3.4. Market Revenue and Volume Forecast, by Route of Administration

13.3.5. Market Revenue and Volume Forecast, by End-User

13.3.6. India

13.3.6.1. Market Revenue and Volume Forecast, by Drug Class

13.3.6.2. Market Revenue and Volume Forecast, by Infection Type

13.3.6.3. Market Revenue and Volume Forecast, by Indication

13.3.6.4. Market Revenue and Volume Forecast, by Route of Administration

13.3.7. Market Revenue and Volume Forecast, by End-User

13.3.8. China

13.3.8.1. Market Revenue and Volume Forecast, by Drug Class

13.3.8.2. Market Revenue and Volume Forecast, by Infection Type

13.3.8.3. Market Revenue and Volume Forecast, by Indication

13.3.8.4. Market Revenue and Volume Forecast, by Route of Administration

13.3.9. Market Revenue and Volume Forecast, by End-User

13.3.10. Japan

13.3.10.1. Market Revenue and Volume Forecast, by Drug Class

13.3.10.2. Market Revenue and Volume Forecast, by Infection Type

13.3.10.3. Market Revenue and Volume Forecast, by Indication

13.3.10.4. Market Revenue and Volume Forecast, by Route of Administration

13.3.10.5. Market Revenue and Volume Forecast, by End-User

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Volume Forecast, by Drug Class

13.3.11.2. Market Revenue and Volume Forecast, by Infection Type

13.3.11.3. Market Revenue and Volume Forecast, by Indication

13.3.11.4. Market Revenue and Volume Forecast, by Route of Administration

13.3.11.5. Market Revenue and Volume Forecast, by End-User

13.4. MEA

13.4.1. Market Revenue and Volume Forecast, by Drug Class

13.4.2. Market Revenue and Volume Forecast, by Infection Type

13.4.3. Market Revenue and Volume Forecast, by Indication

13.4.4. Market Revenue and Volume Forecast, by Route of Administration

13.4.5. Market Revenue and Volume Forecast, by End-User

13.4.6. GCC

13.4.6.1. Market Revenue and Volume Forecast, by Drug Class

13.4.6.2. Market Revenue and Volume Forecast, by Infection Type

13.4.6.3. Market Revenue and Volume Forecast, by Indication

13.4.6.4. Market Revenue and Volume Forecast, by Route of Administration

13.4.7. Market Revenue and Volume Forecast, by End-User

13.4.8. North Africa

13.4.8.1. Market Revenue and Volume Forecast, by Drug Class

13.4.8.2. Market Revenue and Volume Forecast, by Infection Type

13.4.8.3. Market Revenue and Volume Forecast, by Indication

13.4.8.4. Market Revenue and Volume Forecast, by Route of Administration

13.4.9. Market Revenue and Volume Forecast, by End-User

13.4.10. South Africa

13.4.10.1. Market Revenue and Volume Forecast, by Drug Class

13.4.10.2. Market Revenue and Volume Forecast, by Infection Type

13.4.10.3. Market Revenue and Volume Forecast, by Indication

13.4.10.4. Market Revenue and Volume Forecast, by Route of Administration

13.4.10.5. Market Revenue and Volume Forecast, by End-User

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Volume Forecast, by Drug Class

13.4.11.2. Market Revenue and Volume Forecast, by Infection Type

13.4.11.3. Market Revenue and Volume Forecast, by Indication

13.4.11.4. Market Revenue and Volume Forecast, by Route of Administration

13.4.11.5. Market Revenue and Volume Forecast, by End-User

13.5. Latin America

13.5.1. Market Revenue and Volume Forecast, by Drug Class

13.5.2. Market Revenue and Volume Forecast, by Infection Type

13.5.3. Market Revenue and Volume Forecast, by Indication

13.5.4. Market Revenue and Volume Forecast, by Route of Administration

13.5.5. Market Revenue and Volume Forecast, by End-User

13.5.6. Brazil

13.5.6.1. Market Revenue and Volume Forecast, by Drug Class

13.5.6.2. Market Revenue and Volume Forecast, by Infection Type

13.5.6.3. Market Revenue and Volume Forecast, by Indication

13.5.6.4. Market Revenue and Volume Forecast, by Route of Administration

13.5.7. Market Revenue and Volume Forecast, by End-User

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Volume Forecast, by Drug Class

13.5.8.2. Market Revenue and Volume Forecast, by Infection Type

13.5.8.3. Market Revenue and Volume Forecast, by Indication

13.5.8.4. Market Revenue and Volume Forecast, by Route of Administration

13.5.8.5. Market Revenue and Volume Forecast, by End-User

Chapter 14. Company Profiles

14.1. Pfizer Inc.

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Merck & Co., Inc.

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Novartis AG

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Bayer AG

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Johnson & Johnson

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Gilead Sciences, Inc.

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Sanofi S.A.

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. AbbVie Inc.

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Bristol-Myers Squibb Company

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. GlaxoSmithKline plc

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms